EU/3/19/2212: Orphan designation for the treatment of Friedreich’s ataxia

leriglitazone

Table of contents

Overview

On 17 October 2019, orphan designation EU/3/19/2212 was granted by the European Commission to Minoryx Therapeutics S.L., Spain, for leriglitazone (also known as MIN-102) for the treatment of Friedreich’s ataxia.

Key facts

Active substance
leriglitazone
Intended use
Treatment of Friedreich’s ataxia
Orphan designation status
Positive
EU designation number
EU/3/19/2212
Date of designation
17/10/2019
Sponsor

Minoryx Therapeutics S.L.
Calle Ernest Lluch 32 Tcm 2
08302 Mataro Barcelona
Spain
Tel: +34935441466
E-mail: xortega@minoryx.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating